{"id":"https://openalex.org/W2324294368","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","title":"A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID)","display_name":"A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID)","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2324294368","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","mag":"2324294368"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.8109","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015452155","display_name":"Stephen H. Rosenoff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Rosenoff","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087372519","display_name":"N. Gabrail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Gabrail","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":null,"display_name":"R. Conklin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Conklin","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020638079","display_name":"John A. Hohneker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Hohneker","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044216486","display_name":"William J. Berg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Berg","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Hedrick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Hedrick","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061127270","display_name":"Ghulam M. Warsi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Warsi","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Benedetto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Benedetto","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004844925","display_name":"Weiping Zhu","orcid":"https://orcid.org/0000-0002-8856-5609","observed_orcids":["https://orcid.org/0000-0002-8856-5609"]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Zhu","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005448318","display_name":"Lowell Brian Anthony","orcid":"https://orcid.org/0000-0001-7348-7874","observed_orcids":["https://orcid.org/0000-0001-7348-7874"]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]},{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Anthony","raw_affiliation_strings":["Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA","institution_ids":["https://openalex.org/I4210100169","https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"8109","last_page":"8109"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11785","display_name":"Nausea and vomiting management","score":0.70169997215271,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11785","display_name":"Nausea and vomiting management","score":0.70169997215271,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.030500000342726707,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.028300000354647636,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chemotherapy-induced-diarrhea","display_name":"chemotherapy-induced diarrhea","score":0.8690000176429749},{"id":"https://openalex.org/keywords/long-acting-octreotide","display_name":"long-acting octreotide","score":0.9629999995231628},{"id":"https://openalex.org/keywords/somatostatin-analogs","display_name":"somatostatin analogues","score":0.9269999861717224},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6759999990463257},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.6729999780654907},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.8960000276565552},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":0.8420000076293945},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9300000071525574},{"id":"https://openalex.org/keywords/chemotherapy-side-effects","display_name":"chemotherapy side effects","score":0.593999981880188},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.8740000128746033},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7609999775886536},{"id":"https://openalex.org/keywords/interim-analysis","display_name":"interim analysis","score":0.4020000100135803},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.3149999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9665235280990601},{"id":"https://openalex.org/C2781025020","wikidata":"https://www.wikidata.org/wiki/Q419935","display_name":"Octreotide","level":3,"score":0.7260909676551819},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6599166393280029},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.6517757177352905},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.6429611444473267},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5813534259796143},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5321919918060303},{"id":"https://openalex.org/C162156334","wikidata":"https://www.wikidata.org/wiki/Q473420","display_name":"Dose","level":2,"score":0.4906681776046753},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39033013582229614},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.33375996351242065},{"id":"https://openalex.org/C2776297358","wikidata":"https://www.wikidata.org/wiki/Q407166","display_name":"Somatostatin","level":2,"score":0.2514685094356537}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.8109","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.8109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.8109","doi":"https://doi.org/10.1200/jco.2004.22.90140.8109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.8109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W23408028","https://openalex.org/W4239526490","https://openalex.org/W2102965186","https://openalex.org/W2081242874","https://openalex.org/W2036630130","https://openalex.org/W2461717879","https://openalex.org/W2414294178","https://openalex.org/W2247083811","https://openalex.org/W2685245312","https://openalex.org/W1895902603"],"abstract_inverted_index":{"8109":[0],"Background:":[1],"Diarrhea":[2],"is":[3,78],"a":[4,36,102],"common":[5],"side":[6],"effect":[7],"of":[8,33,40,63,73,91,94,104,133,138,185,222,233,247,296,309,320],"chemotherapy":[9,23,123,206],"and":[10,54,97,120,160,176,258,266,274,278,286,313],"can":[11],"be":[12,46,112],"dose-limiting":[13],"in":[14,22,48,51,58,99,197,317],"some":[15],"patients":[16],"(pts).":[17],"Severe":[18],"diarrhea":[19,234,250],"often":[20],"results":[21],"delay":[24],"and/or":[25],"dose-reduction,":[26],"potentially":[27],"reducing":[28],"the":[29,61,89,194,223,226,241,244,297,318],"overall":[30,245],"therapeutic":[31],"benefit":[32],"treatment.":[34],"Octreotide,":[35],"synthetic":[37],"octapeptide":[38],"analogue":[39],"somatostatin,":[41],"has":[42,55,301],"been":[43,56,302],"shown":[44],"to":[45,87,111,127,130],"effective":[47],"controlling":[49],"CTID":[50,64,119,322],"previous":[52],"studies":[53],"recommended":[57],"guidelines":[59],"for":[60,122,212,261,281],"treatment":[62,154,254],"(Wadler":[65],"et":[66],"al,":[67],"JCO":[68],"16:1998).":[69],"The":[70,143],"long-acting":[71],"formulation":[72],"octreotide":[74],"(Sandostatin":[75],"LAR\u00ae":[76],"Depot)":[77],"administered":[79],"by":[80,238],"monthly":[81],"injection.":[82,142],"This":[83],"trial":[84],"was":[85,169,255,275],"designed":[86],"study":[88,227,253],"effects":[90],"two":[92,195],"dosages":[93],"LAR,":[95],"30mg":[96,135],"40mg,":[98],"pts":[100,108,173,178,224,262,282,300],"with":[101,115,152,215,228],"history":[103],"CTID.":[105],"Methods:":[106],"150":[107],"were":[109,124,147,163,174,188,209],"planned":[110],"enrolled.":[113],"Pts":[114],"active":[116],"or":[117,136,205,329,332],"recent":[118,231],"scheduled":[121,298],"randomly":[125],"assigned":[126],"receive":[128],"up":[129],"6":[131],"doses":[132,146,184],"either":[134],"40mg":[137],"LAR":[139,269,289,310,314],"via":[140],"IM":[141],"first":[144],"2":[145,183],"given":[148],"7\u201314":[149],"days":[150],"apart":[151],"subsequent":[153],"delivered":[155],"q":[156],"28d.":[157],"AEs,":[158],"QOL,":[159],"pt":[161],"diaries":[162],"collected.":[164],"Results:":[165],"An":[166],"interim":[167,242],"analysis":[168,243],"performed":[170],"after":[171],"118":[172],"enrolled":[175],"81":[177],"had":[179],"received":[180],"at":[181,271,291,304],"least":[182],"LAR.":[186],"There":[187],"no":[189],"statistically":[190],"significant":[191],"differences":[192],"between":[193],"dose-groups":[196],"age,":[198],"sex,":[199],"race,":[200],"weight,":[201],"primary":[202],"tumor":[203],"type":[204],"regimens.":[207],"80.5%":[208],"being":[210,235],"treated":[211],"colorectal":[213],"carcinoma":[214],"50%":[216],"receiving":[217],"5-FU/LV":[218],"+/-":[219],"CPT-11.":[220],"49%":[221],"entered":[225],"their":[229],"most":[230],"episode":[232],"grade":[236,248],"III/IV":[237,249],"NCI-CTC.":[239],"At":[240],"incidence":[246],"while":[251],"on":[252,263,283],"38%":[256],"(n=39)":[257],"33%":[259],"(n=42)":[260],"30":[264,284,311],"mg":[265,268,285,288,312,316],"40":[267,287,315],"respectively":[270,290],"Dose":[272,292],"2,":[273],"36%":[276],"(n=28)":[277,280],"43%":[279],"3.":[293],"Conclusions:":[294],"Accrual":[295],"151":[299],"completed":[303],"43":[305],"US":[306],"sites.":[307],"Assessment":[308],"management":[319],"recurrent":[321],"awaits":[323],"further":[324],"follow-up.":[325],"Author":[326],"Disclosure":[327],"Employment":[328],"Leadership":[330],"Consultant":[331],"Advisory":[333],"Stock":[334],"Ownership":[335],"Honoraria":[336],"Research":[337],"Funding":[338],"Expert":[339],"Testimony":[340],"Other":[341],"Remuneration":[342],"Novartis":[343,346,349,352,355],"Pharmaceuticals":[344,347,350,353,356],"Corp.":[345,348,351,354],"Corporation":[357]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}